Efficacy of FOLFIRI as a second -line in extrapulmonary poorly differentiated neuroendocrine carcinoma

被引：0
|
作者：
Fabregat-Franco, Carles [1 ]
Munoz, M. Nieva [2 ]
Martin, F. Perez [3 ]
Ruffinelli, J. [2 ]
Vivas, C. Santos [4 ,5 ]
Sanchez, C. [6 ]
Salazar, R. [7 ,8 ]
Teule, A. [9 ]
机构：
[1] Inst Catalan Oncol, Lhospitalet De Llobregat, Spain
[2] Catalan Inst Oncol, Lhospitalet De Llobregat, Spain
[3] IDIBELL, Clin Res Unit, Inst Catala Oncol ICO Lhospitalet, Lhospitalet De Llobregat, Spain
[4] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[5] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[7] Inst Catala Oncol, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[8] Inst Catala Oncol, IDIBELL, Lhospitalet De Llobregat, Spain
[9] Inst Catala Oncol, Dept Med Oncol, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz155.309
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P 310
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
    Apostolidis, Leonidas
    Bergmann, Frank
    Jaeger, Dirk
    Winkler, Eva Caroline
    CANCER MEDICINE, 2016, 5 (09): : 2261 - 2267
  • [2] Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma
    McGarrah, Patrick W.
    Leventakos, Konstantinos
    Hobday, Timothy J.
    Molina, Julian R.
    Finnes, Heidi D.
    Westin, Gustavo F.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2020, 49 (04) : 529 - 533
  • [3] Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Sato, Mariko
    Nishibori, Riko
    Nozawa, Kazuki
    Kitagawa, Chiyoe
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (03) : 947 - 951
  • [4] Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma
    Keiji Sugiyama
    Kazuhiro Shiraishi
    Mariko Sato
    Riko Nishibori
    Kazuki Nozawa
    Chiyoe Kitagawa
    Journal of Gastrointestinal Cancer, 2021, 52 : 947 - 951
  • [5] Efficacy of 2nd-line Chemotherapy in Patients With Poorly Differentiated, High Grade Extrapulmonary Neuroendocrine Carcinoma (PD NEC)
    McGarrah, Patrick
    Leventakos, Konstantinos
    Westin, Gustavo
    Finnes, Heidi
    Molina, Julian
    Hobday, Timothy
    Halfdanarson, Thorvardur
    PANCREAS, 2019, 48 (03) : 446 - 446
  • [6] Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC).
    McGarrah, Patrick Walsh
    Leventakos, Konstantinos
    Hobday, Timothy J.
    Molina, Julian R.
    Finnes, Heidi Diann
    Halfdanarson, Thorvardur Ragnar
    Westin, Gustavo Figueiredo Marcondes
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
    C. De Divitiis
    C. von Arx
    A. M. Grimaldi
    D. Cicala
    F. Tatangelo
    A. Arcella
    G. M. Romano
    E. Simeone
    R. V. Iaffaioli
    P. A. Ascierto
    S. Tafuto
    Journal of Translational Medicine, 14
  • [8] Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
    De Divitiis, C.
    von Arx, C.
    Grimaldi, A. M.
    Cicala, D.
    Tatangelo, F.
    Arcella, A.
    Romano, G. M.
    Simeone, E.
    Iaffaioli, R. V.
    Ascierto, P. A.
    Tafuto, S.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [9] Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience
    Bardasi, C.
    Caputo, F.
    Santini, C.
    Cerma, K.
    Gardini, Casadei A.
    Andrikou, K.
    Salati, M.
    Fontana, A.
    Spallanzani, A.
    Bertolini, F.
    Luppi, G.
    Gelsomino, F.
    NEUROENDOCRINOLOGY, 2020, 110 : 180 - 180
  • [10] Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)
    Bardasi, C.
    Spallanzani, A.
    Luppi, G.
    Bertolini, F.
    Fontana, A.
    Salati, M.
    Caputo, F.
    Santini, C.
    Cerma, K.
    Dominici, M.
    Gelsomino, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 156 - 156
12345